[Media Releases] [Korea Economic Daily] Forerunner in novel drug development, LegoChem Biosciences (12 Jan 2015)

Title:  Forerunner in novel drug development, LegoChem Biosciences

Publication: The Korea Economic Daily (Hankyung) / WowTV

Date: 12 Jan 2015

Summary

·         Founded in 2006, LegoChem Biosciences is a biopharmaceutical specializing in novel drug discovery/development based on medicinal chemistry. LegoChem’s business model is to research and develop to early stage and then out-license to pharmas and biotechs.

·         LegoChem aims to leap forward to become a global pharmaceutical company with Antibody-Drug Conjugates (ADCs) technology, which combines the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drug.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).